Symbolbild · KI-generiert
Fennec Pharmaceuticals Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK® received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI®.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Fennec Pharmaceuticals Inc. | FRX | TSX | 346 Mio. USD |
| Compass Therapeutics, Inc. | CMPX | NASDAQ | 344 Mio. USD |
| TECSYS Inc. | TCS | TSX | 344 Mio. USD |
| Upstream Bio, Inc. | UPB | NASDAQ | 343 Mio. USD |
| Carlsmed, Inc. | CARL | NASDAQ | 342 Mio. USD |
| DiaMedica Therapeutics Inc. | DMAC | NASDAQ | 342 Mio. USD |
| Standard BioTools Inc. | LAB | NASDAQ | 340 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.